NCT06008119View on ClinicalTrials.gov

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

PHASE3RecruitingINTERVENTIONAL

Enrollment

165

Participants

Timeline

Start Date

October 25, 2023

Primary Completion Date

December 24, 2026

Study Completion Date

December 24, 2026

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG

Tunlametinib plus Vemurafenib

12mg BID Tunlametinib+720mg BID Vemurafenib

DRUG

Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab

According to investigators' suggestion

Trial Locations (1)

Unknown

RECRUITING

Beijing Oncology Hospital, Beijing

All Listed Sponsors

lead

Shanghai Kechow Pharma, Inc.

INDUSTRY

NCT06008119 - Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter